Citi analyst Liav Abraham believes Allergan's pipeline remains largely out of the share price. In a research not titled "Emerging from the Twilight Zone. Reiterating Buy Rating," the analyst admits the outcome of the Restasis district court litigation remains a near-term overhang on the stock. She believes, however, that Allergan's pipeline will become a "more meaningful part of the debate heading into 2018." The company's nonalcoholic steatohepatitis opportunity, as well as its migraine assets, could generate $3B in peak non-risk-adjusted sales, which is largely not discounted in the current valuation, Abraham contends. She lowered her price target for Allergan shares to $280 from $290 and keeps a Buy rating on the name.